Dr. Alex DeLaney is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati.
Alex received her Ph.D. in cell and molecular biology from the University of Pennsylvania where she gained research experience in immunology, molecular biology, bacteriology, and parasitology. Her graduate work focused on the role cell death plays in activating the innate immune response to promote host survival during bacterial and parasitic infections.
Dr. Alex DeLaney is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati.
Alex received her Ph.D. in cell and molecular biology from the University of Pennsylvania where she gained research experience in immunology, molecular biology, bacteriology, and parasitology. Her graduate work focused on the role cell death plays in activating the innate immune response to promote host survival during bacterial and parasitic infections.
- J.D., University of Pennsylvania Law SchoolOrder of the Coif
- Ph.D., Cell and Molecular Biology, University of Pennsylvania
Recipient, National Sciences Foundation Graduate Fellowship
- B.S., Physiology and Neuroscience, University of California, San Diego
- B.A., Psychology, University of California, San Diego
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., University of Pennsylvania Law SchoolOrder of the Coif
- Ph.D., Cell and Molecular Biology, University of Pennsylvania
Recipient, National Sciences Foundation Graduate Fellowship
- B.S., Physiology and Neuroscience, University of California, San Diego
- B.A., Psychology, University of California, San Diego
- State Bar of California
- U.S. Patent and Trademark Office
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
- Privacy Policy
- Terms of Use
- Accessibility